BibTex RIS Cite

Bronkopulmoner Displazide Önleyici Ve Tedavi Amaçlı İnhale Veya Sistemik Steroid Kullanımı: Güncel Bir Derleme

Year 2009, Volume: 3 Issue: 3, 58 - 63, 01.06.2009

Ömer Erdeve S. Ümit Sarıcı

Abstract

Bronkopulmoner displazi patogenezinde mekanik ventilasyon kaynaklı basınç ve/veya hacim travması, oksijen toksisitesi, enfeksiyon, azalmış surfaktan üretimi ve artmış akciğer kan akımı ile ilişkilendirilen inflamasyon suçlanır. İnflamasyon sürecinin durdurulması amaçlı sistemik ve inhale steroidler kullanılmaktadır. Bu yazıda, bronkopulmoner displazi tedavisinde kullanılan sistemik ve inhale steroidlerin gözden geçirilmesi ve bu konuda varılan görüş birliğinin tartışılması amaçlanmıştır.

Keywords

Bronkopulmoner displazi prematürite steroid tedavi

References

  • Bhandari A, Schramm CM, Kimble C, Pappagallo M, Hussain N. Effect of a short course of prednisolone in infants with oxygen dependent bronchopulmonary dysplasia. Pediatrics 2008;121:344
  • Bancalari E. Changes in the pathogenesis and prevention of chro- nic lung disease of prematurity. Am J Perinatol 2001;18:1–9.
  • Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee Sk, Ohlsson A. Changes in the use of postnatal steroids for BPD in 3 large neonatal networks. Pediatrics 2006;118:1328-1335.
  • Hallman M, Peltoniemi O, Saarela T. Early neonatal hydrocortiso- ne: study rather than treat. Pediatrics 2006;118:2540-2542.
  • Eichenwald EC, Stark AR. Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia? Arch Dis Child Fetal Neonatal Ed 2007;92:334-337.
  • Thebaud B, Watterberg K. Postnatal glucocorticoids in very preterm infants: “The good, the bad, and the ugly”? Pediatrics ;107;413-415. Jones BO, Davies MW. Total steroid dose given to ventilated new- born infants with chronic lung disease. J Paediatr Child Health ;43:40-43. Cole CH, Colton T, Shah B, Abbasi S, MacKinnon BL, Demisse S, Frantz ID 3rd. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999;340:1005
  • Zimmerman JJ, Gabbert D, Shivpuri C, Kayata S, Miller J, Ciesi- elski W. Meter-dosed, inhaled beclomethasone initiated at birth to prevent bronchopulmonary dysplasia. Pediatr Crit Care Med ;1:140-145. Cummings JJ, D’Eugionio DB, Gross SJ. A controlled trial of de- xamethasone in preterm infants at high risk of bronchopulmo- nary dysplasia. N Engl J Med 1989;320:1505-1510.
  • American Academy of Pediatrics, Canadian Paediatric Society. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:330-338.
  • Canadian Paediatric Society. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. J Paediatr Child Health 2002;7:20-28.
  • Barrington KJ. The adverse neuro-developmental effects of post- natal steroids in the preterm infant: a systemic review of RCTs. BCM Pediatrics 2001;1:1.
  • Yeh TF, Lin YJ, Lin HC,Huang CC, Hsieh WS, Lin CH, Tsai CH. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350:1304
  • Parikh NA, Lasky RE, Kennedy KA, Moya FR, Hochhauser L, Romo S, Tyson JE. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics ;119:265-272. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 ho- urs) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:1146.
  • Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:1144.
  • Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:1145.
  • Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB: DART Study Investigators. Low dose dexamethasone facilitates extubati- on among chronically ventilator-dependent infants: A multicenter, international, randomized, controlled trial. Pediatrics 2006;117:75
  • Smolkin T, Steinberg M, Sujov E, Mezer E, Tamir A, Makhoul IR. Late postnatal systemic steroids predispose to retinopathy of prematurity in very-low-birth-weight infants: a comparative study. Acta Paediatrica 2008;97:322-326.
  • Ohlsson A, Calvert SA, Hosking M, Shennan AT. Randomized controlled trial of dexamethasone treatment in very-low-birth- weight infants with ventilator-dependent chronic lung disease. Acta Paediatr 1992;81:751–756.
  • Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with broncho- pulmonary dysplasia. Pediatrics 1985;75:106–111.
  • Powell K, Kerkering KW, Barker G, Rozycki HJ. Dexamethasone dosing, mechanical ventilation and the risk of cerebral palsy. J Ma- ternal Fetal Neonatal Med 2006;19:43-48.
  • Fok TF, Lam K, Dolovich M, Ng PC, Wong W, Cheung KL, So KW. Randomised controlled study of early use of inhaled corti- costeroid in preterm infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1999;80:203–208.
  • Merz U, Kusenbach G, Hausler M, Peschgens T, Hornchen H. In- haled budesonide in ventilator-dependent preterm infants: a ran- domized, double-blind pilot study. Biol Neonate 1999;75:46–53.
  • Denjean A, Paris-Llado J, Zupan V, Debillon T, Kieffer F, Magny JF, Desfreres L, Llanas B, Guimaraes H, Moriette G, Voyer M, Dehan M, Breart G. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double blind study. Eur J Pediatr 1998;157:926–931.
  • Arnon S, Grigg J, Silverman M. Effectiveness of budesonide aero- sol in ventilator-dependent preterm babies: a preliminary report. Pediatr Pulmonol 1996;21:231–235.
  • Giep T, Raibble P, Zuerlein T, Schwartz ID. Trial of beclomethaso- ne dipropionate by metered-dose inhaler in ventilator-dependent neonates less than 1500 grams. Am J Perinatol 1996;13:5–9.
  • Dugas MA, Nguyen D, Frenette L, Lachance C, St-Onge O, Fou- geres A, Belanger S, Caouette G, Proulx E, Racine MC, Piedboeuf B. Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediatrics 2005;115:566–572.
  • Pantalitschka T, Poets CF. Inhaled drugs for prevention and treatment of bronchopulmonary dysplasia. Pediatr Pulmonol ;41:703-708.

INHALED OR SYSTEMIC STEROID USE FOR PREVENTIVE AND MANAGEMENT PURPOSES IN BRONCHOPULMONARY DYSPLASIA: A CURRENT REVIEW

Year 2009, Volume: 3 Issue: 3, 58 - 63, 01.06.2009

Ömer Erdeve S. Ümit Sarıcı

Abstract

Inflammation related to mechanical ventilation induced baro and/or volume trauma, oxygen toxicity, infection, decreased surfactant production and increased pulmonary blood flow is accused for bronchopulmonary dysplasia pathogenesis. Systemic or inhalated steroids are used to stop the inflammatory process. Herein, it is aimed to review the systemic and inhalated steroids used in bronchopulmonary dysplasia and discuss the consensus in this subject

Keywords

Bronchopulmonary dysplasia prematurity steroid treatment

References

  • Bhandari A, Schramm CM, Kimble C, Pappagallo M, Hussain N. Effect of a short course of prednisolone in infants with oxygen dependent bronchopulmonary dysplasia. Pediatrics 2008;121:344
  • Bancalari E. Changes in the pathogenesis and prevention of chro- nic lung disease of prematurity. Am J Perinatol 2001;18:1–9.
  • Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee Sk, Ohlsson A. Changes in the use of postnatal steroids for BPD in 3 large neonatal networks. Pediatrics 2006;118:1328-1335.
  • Hallman M, Peltoniemi O, Saarela T. Early neonatal hydrocortiso- ne: study rather than treat. Pediatrics 2006;118:2540-2542.
  • Eichenwald EC, Stark AR. Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia? Arch Dis Child Fetal Neonatal Ed 2007;92:334-337.
  • Thebaud B, Watterberg K. Postnatal glucocorticoids in very preterm infants: “The good, the bad, and the ugly”? Pediatrics ;107;413-415. Jones BO, Davies MW. Total steroid dose given to ventilated new- born infants with chronic lung disease. J Paediatr Child Health ;43:40-43. Cole CH, Colton T, Shah B, Abbasi S, MacKinnon BL, Demisse S, Frantz ID 3rd. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999;340:1005
  • Zimmerman JJ, Gabbert D, Shivpuri C, Kayata S, Miller J, Ciesi- elski W. Meter-dosed, inhaled beclomethasone initiated at birth to prevent bronchopulmonary dysplasia. Pediatr Crit Care Med ;1:140-145. Cummings JJ, D’Eugionio DB, Gross SJ. A controlled trial of de- xamethasone in preterm infants at high risk of bronchopulmo- nary dysplasia. N Engl J Med 1989;320:1505-1510.
  • American Academy of Pediatrics, Canadian Paediatric Society. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:330-338.
  • Canadian Paediatric Society. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. J Paediatr Child Health 2002;7:20-28.
  • Barrington KJ. The adverse neuro-developmental effects of post- natal steroids in the preterm infant: a systemic review of RCTs. BCM Pediatrics 2001;1:1.
  • Yeh TF, Lin YJ, Lin HC,Huang CC, Hsieh WS, Lin CH, Tsai CH. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350:1304
  • Parikh NA, Lasky RE, Kennedy KA, Moya FR, Hochhauser L, Romo S, Tyson JE. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics ;119:265-272. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 ho- urs) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:1146.
  • Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:1144.
  • Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:1145.
  • Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB: DART Study Investigators. Low dose dexamethasone facilitates extubati- on among chronically ventilator-dependent infants: A multicenter, international, randomized, controlled trial. Pediatrics 2006;117:75
  • Smolkin T, Steinberg M, Sujov E, Mezer E, Tamir A, Makhoul IR. Late postnatal systemic steroids predispose to retinopathy of prematurity in very-low-birth-weight infants: a comparative study. Acta Paediatrica 2008;97:322-326.
  • Ohlsson A, Calvert SA, Hosking M, Shennan AT. Randomized controlled trial of dexamethasone treatment in very-low-birth- weight infants with ventilator-dependent chronic lung disease. Acta Paediatr 1992;81:751–756.
  • Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with broncho- pulmonary dysplasia. Pediatrics 1985;75:106–111.
  • Powell K, Kerkering KW, Barker G, Rozycki HJ. Dexamethasone dosing, mechanical ventilation and the risk of cerebral palsy. J Ma- ternal Fetal Neonatal Med 2006;19:43-48.
  • Fok TF, Lam K, Dolovich M, Ng PC, Wong W, Cheung KL, So KW. Randomised controlled study of early use of inhaled corti- costeroid in preterm infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1999;80:203–208.
  • Merz U, Kusenbach G, Hausler M, Peschgens T, Hornchen H. In- haled budesonide in ventilator-dependent preterm infants: a ran- domized, double-blind pilot study. Biol Neonate 1999;75:46–53.
  • Denjean A, Paris-Llado J, Zupan V, Debillon T, Kieffer F, Magny JF, Desfreres L, Llanas B, Guimaraes H, Moriette G, Voyer M, Dehan M, Breart G. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double blind study. Eur J Pediatr 1998;157:926–931.
  • Arnon S, Grigg J, Silverman M. Effectiveness of budesonide aero- sol in ventilator-dependent preterm babies: a preliminary report. Pediatr Pulmonol 1996;21:231–235.
  • Giep T, Raibble P, Zuerlein T, Schwartz ID. Trial of beclomethaso- ne dipropionate by metered-dose inhaler in ventilator-dependent neonates less than 1500 grams. Am J Perinatol 1996;13:5–9.
  • Dugas MA, Nguyen D, Frenette L, Lachance C, St-Onge O, Fou- geres A, Belanger S, Caouette G, Proulx E, Racine MC, Piedboeuf B. Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediatrics 2005;115:566–572.
  • Pantalitschka T, Poets CF. Inhaled drugs for prevention and treatment of bronchopulmonary dysplasia. Pediatr Pulmonol ;41:703-708.
There are 26 citations in total.

Details

Other ID JA73SY75ZZ
Journal Section Collection
Authors

Ömer Erdeve This is me

S. Ümit Sarıcı This is me

Publication Date June 1, 2009
Submission Date June 1, 2009
Published in Issue Year 2009 Volume: 3 Issue: 3

Cite

Vancouver Erdeve Ö, Sarıcı SÜ. INHALED OR SYSTEMIC STEROID USE FOR PREVENTIVE AND MANAGEMENT PURPOSES IN BRONCHOPULMONARY DYSPLASIA: A CURRENT REVIEW. Turkish J Pediatr Dis. 2009;3(3):58-63.


The publication language of Turkish Journal of Pediatric Disease is English.


Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 7 articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.


The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.